Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Ianalumab in Primary Sjogren's Syndrome
NCT02962895Phase 2Completed
- Sponsor
- Novartis
- Start
- Jun 2017
- Primary completion
- Jun 2020
- Modality
- Monoclonal Antibodies
- Countries
- 19
01
Overview
A Phase 2 trial of ianalumab, sponsored by Novartis. Started Jun 2017; status: completed.
02
Drugs
ianalumab
Beyond the preview
Go deeper on NCT02962895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02962895.